The percentage of patients taking cholinesterase inhibitors did not differ between the dementia groups whereas, as expected, significantly more Lewy body dementia patients were taking dopaminergic medication compared to the Alzheimer’s disease group. This evidence concerns the gene BCHE and Alzheimer disease.